UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	/AL
OMB Number:	3235-0287
Estimated average but	rden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person * Binder Gwendolyn				2. Issuer Name and Ticker or Trading Symbol Cabaletta Bio, Inc. [CABA]					5. R	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600				3. Date of Earliest Transaction (Month/Day/Year) 10/24/2019					X	X Officer (give title below) Other (specify below) EVP, Science & Technology)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)					_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
PHILADELPHIA, PA 19104 (City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						es Acquired	ired, Disposed of, or Beneficially Owned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year					ate, if 3	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		d 5. Amount of Securities Benefit		neficially	5. 7 Ownership o Form: E	Beneficial	
			(Month/Day		Year)	Code	e V A	(A) or (D)	(Ins	nstr. 3 and 4)		o (Direct (D) (or Indirect (I) (Instr. 4)	Ownership Instr. 4)	
Reminder:								in this f	s who respon orm are not r s a currently	equired to	respond	unless the		ed SEC 14	174 (9-02)
Reminder:	*							Davasa							
Title of Derivative	Conversion		3A. Deemed Execution Date, if	4. Transac	ts, cal	lls, warr 5. Numb of Deriva	er ative	in this f displays nired, Dispo options, con 6. Date Exe Expiration I	orm are not r s a currently sed of, or Bene recisable and Date	equired to valid OMB eficially Ow ities) 7. Title and of Underly	respond control r ned	8. Price of Derivative	9. Number of Derivative	f 10. Ownershi	11. Natu
Title of Derivative	Conversion		3A. Deemed Execution Date, if	4. Transac Code	tion (<mark>lls, warr</mark> 5. Numb	er ative es d (A)	in this f displays aired, Dispo options, con 6. Date Exe	orm are not r s a currently sed of, or Bene recisable and Date	equired to valid OMB eficially Ow ities)	respond control r ned d Amount ing	unless the number.	9. Number of Derivative Securities Beneficially Owned Following Reported Transactions	f 10. Ownershi Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indire Benefici Ownersi (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion (Ils, warr 5. Numb of Deriva Securitie Acquired or Dispo of (D) (Instr. 3,	er ative es d (A)	in this f displays nired, Dispo options, con 6. Date Exe Expiration I	sed of, or Beneavertible securicisable and Date //Year)	equired to valid OMB eficially Ow ities) 7. Title and of Underly Securities	respond control r ned d Amount ing	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownershi Form of Derivative Security: Direct (D or Indirec	11. Nature of Indire Benefici Ownersi (Instr. 4)

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Binder Gwendolyn C/O CABALETTA BIO, INC. 2929 ARCH STREET, SUITE 600 PHILADELPHIA, PA 19104			EVP, Science & Technology				

Signatures

/s/ Anup Marda, Attorney-in-Fact	10/28/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option vests over four years, with 25% vesting on October 24, 2020, and the remaining shares vesting in 12 equal quarterly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.